Emily L Thomas

US Patent:

20180100151, Apr 12, 2018

Filed:

Dec 7, 2017

Appl. No.:

15/834323

Inventors:

- Pasadena CA, US
Shanthi Ganesh - East Hanover NJ, US
Elizabeth George - Cambridge MA, US
Dieter Heusken - Basel, CH
Stuart Milstein - Cambridge MA, US
Jonathan Solomon - Cambridge MA, US
Emily Thomas - Cambridge MA, US
Ivanka Toudjarska - Cambridge MA, US
Jennifer Tullai - Cambridge MA, US
Jan Weiler - Cambridge MA, US

International Classification:

C12N 15/113
A61K 31/7125
A61K 31/713
A61K 31/7115
A61K 31/712
A61K 45/06
A61K 31/7105

Abstract:

The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

US Patent:

20160010089, Jan 14, 2016

Filed:

Feb 27, 2014

Appl. No.:

14/770765

Inventors:

- Pasadena CA, US
Shanthi Ganesh - East Hanover NJ, US
Elizabeth George - Cambridge MA, US
Dieter Huesken - Basel, CH
Stuart Milstein - Cambridge MA, US
Jonathan Solomon - Cambridge MA, US
Emily Thomas - Cambridge MA, US
Ivanka Toudjarska - Cambridge MA, US
Jennifer Tullai - Cambridge MA, US
Jan Weiler - Cambridge MA, US

International Classification:

C12N 15/113
A61K 45/06
A61K 31/713

Abstract:

The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.